Academic Journals Database
Disseminating quality controlled scientific knowledge

Plaque psoriasis in children and adolescents – the role of etanercept

ADD TO MY LIST
 
Author(s): Ricceri F | Tripo L | Pescitelli L | Prignano F

Journal: Psoriasis : Targets and Therapy
ISSN 2230-326X

Volume: 2012;
Issue: default;
Start page: 25;
Date: 2012;
Original page

ABSTRACT
Federica Ricceri, Lara Tripo, Leonardo Pescitelli, Francesca PrignanoDivision of Clinical, Preventive and Oncology Dermatology, Department of Critical Care Medicine and Surgery, University of Florence, Florence, ItalyBackground: Childhood-onset psoriasis affects approximately one-third of the psoriatic population. Among many potential treatments of childhood psoriasis, biological agents are emerging as a valuable option in the management of this disease. In Europe, etanercept has recently been approved for children aged 6 years and over. Data from a well-designed clinical trial indicate that in children, etanercept effectively reduces psoriasis symptoms, with beneficial effects evident as early as 4 weeks after the onset of therapy. The treatment is generally well tolerated; mild injection site reactions are the most common adverse events reported in the literature. Published data of etanercept use in children show promising results, but further clinical studies are necessary to confirm its long-term efficacy and safety.Keywords: pediatric psoriasis, anti-TNF-α, etanercept
Why do you need a reservation system?      Save time & money - Smart Internet Solutions